OMIRA™ OC Detects 9 in 10 Early-Stage Ovarian Cancers in Independent Validation at ESMO 2026
Study demonstrates that integrating lipids, metabolites, and proteins reveals coordinated molecular signatures missed by traditional single omic tests.
AOA Dx Builds Oncology Platform Across Three Gynecologic Cancers as Lead Ovarian Cancer Assay Advances Toward Commercialization
Study demonstrates that integrating lipids, metabolites, and proteins reveals coordinated molecular signatures missed by traditional single omic tests.
AOA Dx Publishes Peer-Reviewed Study Validating the Biology Behind Its Multi-Omic Approach to Earlier Ovarian Cancer Detection
Study demonstrates that integrating lipids, metabolites, and proteins reveals coordinated molecular signatures missed by traditional single omic tests.
AOA Dx Pioneers Translation of Lipid Biomarkers into a Targeted Multi-omic Assay, Achieving 92% Early-Stage Ovarian Cancer Sensitivity in Symptomatic Women
New results position lipidomics as a powerful new frontier in oncology diagnostics and advance AKRIVIS GD™ toward clinical launch
AOA Dx Enrolls First Patient in APEX Study, Advancing Proprietary Biobank and Clinical Infrastructure
Denver, CO | May 5, 2026 — AOA Dx, Inc. (“AOA”), a diagnostics company focused on transforming the early identification of ovarian cancer, today announced the enrollment of the first participant in its APEX study, a prospective, multi-site study being conducted across the United States and Europe, designed to expand the company’s industry-leading biobank of women […]
AOA Dx Presents New Data at AACR 2026 Advancing a Multi-Omic Blood Test for Early Ovarian Cancer Detection
Denver, CO | April 20, 2026 — AOA Dx today announced the presentation of two new studies at the American Association for Cancer Research (AACR) Annual Meeting 2026, demonstrating significant advancement toward a non-invasive, blood-based test for the early detection of ovarian cancer in women experiencing signs and symptoms. The company is actively preparing for […]
AOA Dx Appoints Globally Recognized LC–MS Expert Cory Bystrom as Senior Director of Biomarker and Analytical Development
Veteran LC-MS leader to guide platform progression from early development through clinical and regulatory stages.
AOA Dx Appoints Chris Roberts as Chief Product Officer to Advance Next-Generation Ovarian Cancer Diagnostics
Seasoned diagnostics leader brings deep expertise in product strategy, commercialization, and market access to launch AKRIVIS GD™ for commercial adoption.
AOA Dx Releases First-Ever Comprehensive Women’s Health Exit Analysis, Revealing $100B+ in Realized Value Over 25 Years
AOA Dx unveiled Follow the Exits: Why Women’s Health Is a Smart Bet in Healthcare at the 2026 J.P. Morgan Healthcare Conference, presenting the first comprehensive analysis of 25 years of realized exits in women’s health. The report documents more than $100B in disclosed exit value and demonstrates that women’s health is a scaled, durable healthcare sector with accelerating momentum across diagnostics, biopharma, and devices.
New Peer-Reviewed Publication Shows Multi-Omic Blood Test Achieves High Sensitivity For Early-Stage Ovarian Cancer Detection
AOA Dx (AOA), a leader in blood-based diagnostics for early cancer detection, has published peer-reviewed clinical evidence showing high accuracy in detecting ovarian cancer in symptomatic women—a group where early diagnosis is essential yet often missed. This breakthrough highlights the potential to transform outcomes for women at risk.